ASCEND BY NTHRYS
Research Abroad Products

Molecular Oncology Project Topics

Browse all focused areas across all project categories under this field.

Showing 205–216 of 220 project topics
Fibroblast-Targeting Therapeutics Discovery Platform
A SaaS-based computational platform that identifies and screens novel compounds targeting cancer-associated fibroblasts in the tumor microenvironment. This enables pharmaceutical companies to accelerate drug development cycles and unlock new therapeutic modalities with reduced time-to-market for stromal-targeting cancer treatments.
Tumor Microenvironment Biotechnology Click to view more details →
Tumor Vascular Normalization Assessment Service
An integrated bioanalytical service combining imaging, biomarker analysis, and computational modeling to evaluate vascular normalization responses in patient tumors and preclinical models. This delivers clinical trial optimization and predictive biomarker value for anti-angiogenic and vascular normalization drug developers.
Tumor Microenvironment Biotechnology Click to view more details →
Immune Cell Infiltration Prediction Engine
An AI-powered software tool that predicts immune cell recruitment and infiltration patterns in tumor microenvironments using multi-omics data integration and machine learning models. This provides pharmaceutical companies with patient stratification capabilities and combination therapy optimization to improve immuno-oncology clinical trial success rates.
Tumor Microenvironment Biotechnology Click to view more details →
Metabolic Reprogramming Biomarker Testing Kit
A standardized diagnostic kit measuring tumor and stromal cell metabolic signatures to identify microenvironment-driven treatment resistance mechanisms. This generates revenue through recurring laboratory testing services while enabling precision oncology companies to develop metabolism-targeting combination therapies.
Tumor Microenvironment Biotechnology Click to view more details →
Stromal-Immune Crosstalk Mapping Technology
A spatial transcriptomics and proteomics service platform that maps intercellular communication networks between stromal and immune cells within intact tumors. This creates licensing opportunities and contract research revenue while enabling biotech clients to design more effective dual-targeting immunotherapeutic strategies.
Tumor Microenvironment Biotechnology Click to view more details →
Tumor Microenvironment Organoid Screening Platform
A high-throughput platform combining engineered organoids with integrated stromal and immune cell components for rapid drug response profiling. This accelerates pharmaceutical development timelines and captures assay service fees while enabling better prediction of clinical efficacy compared to traditional tumor models.
Tumor Microenvironment Biotechnology Click to view more details →
Tumor Mutational Burden Assay Development
Developing and validating next generation sequencing-based tumor mutational burden assays for predicting response to immune checkpoint inhibitor therapy in oncology clinical practice.
Biotech Innovation in Oncology Diagnostics Click to view more details →
Microsatellite Instability Detection Assay Development
Developing PCR and sequencing-based microsatellite instability detection assays as companion diagnostics for immunotherapy in colorectal and endometrial cancer patient selection.
Biotech Innovation in Oncology Diagnostics Click to view more details →
Circulating Tumor DNA Minimal Residual Disease Monitoring
Developing ultra-sensitive ctDNA detection assays for monitoring minimal residual disease after cancer surgery and treatment for predicting relapse and guiding adjuvant therapy decisions.
Biotech Innovation in Oncology Diagnostics Click to view more details →
Proteomics-Based Cancer Subtype Classification
Applying mass spectrometry proteomics for protein-based cancer subtype classification complementing genomic profiling for identifying therapeutically actionable molecular cancer subtypes.
Biotech Innovation in Oncology Diagnostics Click to view more details →
Liquid Biopsy Companion Diagnostic Platform Integration
A cloud-based SaaS platform that integrates liquid biopsy data with electronic health records to deliver real-time companion diagnostic recommendations for targeted cancer therapies. This creates recurring revenue through subscription licensing to hospitals and oncology clinics while enabling pharmaceutical companies to expand companion diagnostic markets.
Biotech Innovation in Oncology Diagnostics Click to view more details →
AI-Powered Pathology Image Analysis Software Suite
A deep learning software tool that automates histopathology slide analysis for cancer diagnosis and grading, reducing diagnostic turnaround time from days to hours. The platform generates B2B SaaS revenue through laboratory licensing fees and white-label partnerships with diagnostic service providers worldwide.
Biotech Innovation in Oncology Diagnostics Click to view more details →